<DOC>
	<DOCNO>NCT00056966</DOCNO>
	<brief_summary>Participants study hematologic malignancy ( disorder bone marrow affect body 's ability create blood ) might benefit receive allogeneic stem cell transplant ( mean cell come donor ) family member nearly identical match donor . The donor may either match sibling , mismatch family member , unrelated person . Usually patient give high dos chemotherapy receive stem cell transplant keep immune system reject donor stem cell kill diseased cell remain body . However , group patient high risk develop possibly life-threatening treatment-related side effect infection , damage vital organ lung , liver , kidney heart , well graft versus host disease ( GVHD ) . Instead high dose chemotherapy radiotherapy usually give transplant , research study use new pre-transplant combination three drug , Fludarabine , Anti-CD45 CAMPATH-1H low dose radiotherapy . Fludarabine chemotherapy drug Anti-CD45 CAMPATH-1H antibody certain type blood cell , include cause disease . CAMPATH-1H particularly important stay active body long time give , mean may work longer prevent GVHD symptom . Anti-CD45 may help eradicate residual malignant cell . All agent also help prevent rejection donor stem cell . This study design give less intense chemotherapy radiotherapy , life-threatening toxicity conventional high dose chemotherapy radiotherapy regimen reduce , maintain ability cure cancer .</brief_summary>
	<brief_title>Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation Patients With Hematological Diseases</brief_title>
	<detailed_description>CAMPATH-1H give daily IV infusion three day . Fludarabine give daily IV infusion four day . Anti-CD45 give daily IV infusion 4 day . Patients receive radiotherapy ( also know Total Body Irradiation TBI ) one day . A summary treatment follow : - Day - 8 : CAMPATH-1H Fludarabine - Day - 7 : CAMPATH-1H Fludarabine - Day - 6 : CAMPATH-1H Fludarabine - Day - 5 : Anti-CD45 Fludarabine - Day - 4 : Anti-CD45 - Day - 3 : Anti-CD45 - Day - 2 : Anti-CD45 - Day - 1 : TBI - Day 0 : Stem Cell Infusion ( transplant ) To help prevent body develop GVHD , patient also receive drug FK506 , start two day transplant continue least one month . Both CAMPATH-1H Anti-CD45 cause allergic reaction patient give drug help prevent reaction receive daily dos . To see CAMPATH-1H work patient hematologic malignancy , patient ask participate pharmacokinetic study . For , approximately 13 blood sample take central line schedule infusion Day -8 Day -6 , daily thereafter Day 0 , approximately per week day 7 , 14 , 21 28 post transplant . No 5 teaspoonful total drawn . To see Anti-CD45 work patient hematologic malignancy patient ask participate pharmacokinetic study . Approximately 22 blood sample take central line schedule , infusion end last infusion Anti-CD45 . No 10 teaspoonful total drawn course four anti-CD45 infusion .</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1 . Patients one follow high risk disease need allogeneic hemopoietic stem cell transplantation : Acute myeloid leukemia either ) Primary refractory , b ) Beyond first complete remission ( CR1 ) , c ) In CR1 high risk relapse Acute lymphoblastic leukemia either ) Primary refractory , b ) Beyond first complete remission ( CR1 ) , c ) In CR1 high risk relapse Chronic myeloid leukemia , either ) Accelerated phase , b ) Blast crisis , c ) Chronic phase achieve major cytogenetic response despite standard therapy Chronic lymphocytic leukemia , either ) Primary refractory , b ) Beyond first complete remission ( CR1 ) , Non Hodgkin 's lymphoma , either ) Primary refractory , b ) Beyond first complete remission ( CR1 ) Hodgkin 's disease , either ) Primary refractory , b ) Beyond first complete remission ( CR1 ) , Myelodysplastic syndrome IPSS score &gt; 0 . ( Appendix A ) Myeloproliferative disorder ( exclusion chronic myeloid leukemia ) ) Primary Myelofibrosis Lile score 1 2 ( Appendix B ) b ) Polycythemia Vera Essential Thrombocythemia transform AML Myelofibrosis PV `` spend phase '' Multiple Myeloma stage II III disease Severe aplastic anemia 2 . Conditions increase Treatment Related Mortality ( need one eligible ) : Greater equal 35 year age ; Ejection Fraction less 50 % ; DLCO le 50 % FEV1/FVC &lt; 80 % predict value ; Diabetes Mellitus ; Renal insufficiency ( serum creatinine abnormal ) ; Hepatic dysfunctiontransaminases , alkaline phosphatase , bilirubin twice upper limit normal ; Prior recent history systemic fungal infection ; Multiple prior treatment regimen ( equal 3 ) ; Significant Grade III IV neurologic , cardiac , pulmonary , renal hepatic toxicity previous treatment ; Prior Autologous Allogeneic Stem Cell transplantation ; 3 . Available Healthy Donor without contraindication donation . 5/6 6/6 relate unrelated donor ( molecular type DRB1 ) ; 4 . Patient and/or responsible person able understand sign consent Pregnant lactate woman , woman unwilling use contraception . HIV positive patient Unstable angina uncompensated congestive heart failure ( Zubrod 3 great ) Severe chronic pulmonary disease require oxygen ( Zubrod 3 great ) Child 's class C cirrhosis Unstable cerebral vascular disease recent hemorrhagic stroke ( le 6 month ) Patients know allergy rat serum product</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's disease</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Myeloproliferative disorder</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Severe aplastic anemia</keyword>
</DOC>